Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch

SOLENO THERAPEUTICS INC

2025-FY EPS reported $0.39 revenue$190,405,000

FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.
Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).
859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.
Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.
First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.